Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study

Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study

Abstract Introduction In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2–4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across the 24-week placebo-controlled period of the DELIVER s...

Full description

Bibliographic Details
Main Authors: Patricia Pozo-Rosich, Messoud Ashina, Stewart J. Tepper, Sidsel Jensen, Line Pickering Boserup, Mette Krog Josiassen, Bjørn Sperling
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-01-01
Series:Neurology and Therapy
Subjects:
Anti-CGRP
Eptinezumab
Migraine
Preventive treatment
Online Access:https://doi.org/10.1007/s40120-023-00575-5

Internet

https://doi.org/10.1007/s40120-023-00575-5

Similar Items